Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.52 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | MC5R | P33032 | 1/20 | 0.48 |
| ▸ | MC3R | P41968 | 1/20 | 0.48 |
| ▸ | MC1R | Q01726 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264768 | 0.94 | IL23R (0.57) | CXCR4IL23RC5AR1OPRM1OPRK1 | |
| SCHEMBL29511552 | 0.91 | CXCR4 (0.57) | CXCR4IL23RC5AR1OPRM1OPRK1 | |
| SCHEMBL30264968 | 0.89 | NPBWR1 (0.53) | IL23RNPBWR1KISS1R | |
| SCHEMBL30264798 | 0.88 | KISS1R (0.52) | CXCR4IL23RC5AR1KISS1R | |
| SCHEMBL30264942 | 0.88 | KISS1R (0.52) | CXCR4IL23RC5AR1KISS1R | |
| SCHEMBL31452905 | 0.88 | CXCR4 (0.62) | CXCR4IL23RC5AR1OPRM1OPRK1 | |
| SCHEMBL30264873 | 0.86 | KISS1R (0.53) | IL23RNPBWR1KISS1R | |
| SCHEMBL30264606 | 0.86 | KISS1R (0.53) | IL23RNPBWR1KISS1R | |
| SCHEMBL30264787 | 0.86 | KISS1R (0.53) | IL23RNPBWR1KISS1R | |
| SCHEMBL30264982 | 0.86 | KISS1R (0.53) | IL23RNPBWR1KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-11-28 | — | — | US | disclosed |
| EP-4392072-A1 | MC4R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028538-A1 | MC4R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391954-A1 | MC4R AGONIST PEPTIDES | MC4R, MC3R, MC5R | CXCR4 1454/4885IL23R 359/4885C5AR1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.